Venous (Vein) Thrombosis - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Venous (Vein) Thrombosis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 90-page report is available in PDF from $2000.

Venous (Vein) Thrombosis - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Venous (Vein) Thrombosis - Pipeline Review, H1 2015’, provides an overview of the Venous (Vein) Thrombosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Venous (Vein) Thrombosis Overview 8
Therapeutics Development 9
Pipeline Products for Venous (Vein) Thrombosis - Overview 9
Pipeline Products for Venous (Vein) Thrombosis - Comparative Analysis 10
Venous (Vein) Thrombosis - Therapeutics under Development by Companies 11
Venous (Vein) Thrombosis - Therapeutics under Investigation by Universities/Institutes 12
Venous (Vein) Thrombosis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Venous (Vein) Thrombosis - Products under Development by Companies 16
Venous (Vein) Thrombosis - Products under Investigation by Universities/Institutes 17
Venous (Vein) Thrombosis - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Bayer AG 19
Bristol-Myers Squibb Company 20
Eisai Co., Ltd. 21
F. Hoffmann-La Roche Ltd. 22
Generex Biotechnology Corporation 23
Merrion Pharmaceuticals Plc 24
Regado Biosciences, Inc. 25
Venous (Vein) Thrombosis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AB-012 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
apixaban - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AS-1468240 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BAY-1213790 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BMS-593214 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
E-5539 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
enoxaparin sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ER-410660 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
fondaparinux sodium - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Ichorcumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NPB-06 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
REG-2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rivaroxaban - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RNAi Oligonucleotide for DVT - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules for Hematological Disorders and Cancer…

For more information open Venous (Vein) Thrombosis - Pipeline Review, H1 2015.


Original Article: Venous (Vein) Thrombosis - Pipeline Review, H1 2015


More From BioPortfolio on "Venous (Vein) Thrombosis - Pipeline Review, H1 2015"

Quick Search


Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...